Bioscrip Infusion Services (HomeChoice Partners, Inc.), Augusta, GA
Is Bioscrip Infusion Services (HomeChoice Partners, Inc.) registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Bioscrip Infusion Services (HomeChoice Partners, Inc.) hold a Georgia pharmacy license?
State board of pharmacy records for Georgia are not checked: no license file or list of board orders was found on the board’s website when checked on November 10, 2026; its license verification is an interactive search.
Has Bioscrip Infusion Services (HomeChoice Partners, Inc.) had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Apr 9, 2020), 1 warning letter close-out (Apr 14, 2022), 1 state referral letter (Apr 26, 2022) and 1 FMD-145 letter (Apr 26, 2022) for Bioscrip Infusion Services (HomeChoice Partners, Inc.). State board of pharmacy records for Georgia are not checked: no license file or list of board orders was found on the board’s website when checked on November 10, 2026; its license verification is an interactive search. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- HomeChoice Partners, Inc.; Bioscrip Infusion Services
- Location
- Augusta, GA
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 1
- Latest action on that page
- Apr 26, 2022
- FDA Data Dashboard inspections
- 0 inspections; 0 published Form 483s
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as HomeChoice Partners, Inc., (dba Bioscrip Infusion Services), a 503A facility, with 5 dated actions.
| Document | |||
|---|---|---|---|
| Apr 26, 2022 | FMD-145 letter | FMD-145 Letter Issued 04/26/2022 | Not linked by FDA |
| Apr 26, 2022 | State referral letter | State Referral Letter Issued 04/26/2022 | FDA copy (archived) |
| Apr 14, 2022 | Warning letter close-out | Warning Letter Close Out Issued 04/14/2022 | Not linked by FDA |
| Aug 9, 2021 | Form 483 | 483 Issued 08/09/2021 | FDA copy (archived) |
| Apr 9, 2020 | Warning letter | Warning Letter (04/09/2020) | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists HomeChoice Partners, Augusta, GA (FEI number 3014461693), matched to this page by exact name, city and state. It lists no classified inspection under this name at that site. Dashboard firm profile.
Form 483s FDA has published for this site
No published Form 483 for FEI 3014461693 was found in the dashboard’s list of published 483s on Nov 15, 2026. FDA publishes only some 483s, so this does not mean none was issued.
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA links 1 Form 483 PDF for Bioscrip Infusion Services (HomeChoice Partners, Inc.), but no observation text is shown, for the reasons below.
Linked 483s whose text is not shown
- Aug 9, 2021: FDA document 157872: the FEI number and firm name on its cover do not match this page by the rule.
State board of pharmacy records
State board of pharmacy records for Georgia are not checked: no license file or list of board orders was found on the board’s website when checked on November 10, 2026; its license verification is an interactive search.
Same name at other locations
FDA lists these records under the same name at another location. A shared name does not establish that they are the same firm.
- Bioscrip Infusion Services (HomeChoice Partners, Inc.), Chesterfield, MO
- Bioscrip Infusion Services (InfuScience, Inc.), Chantilly, VA
This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
Records last pulled Nov 15, 2026. Every entry links to the original public record.